Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
As of today, Pfizer(PFE) shares are valued at $24.44. The company's market cap stands at 138.93B, with a P/E ratio of 14.24 and a dividend yield of 7.0%.
On 2025-11-08, Pfizer(PFE) stock moved within a range of $24.11 to $24.63. With shares now at $24.44, the stock is trading +1.4% above its intraday low and -0.8% below the session's peak.
Trading activity shows a volume of 117.79M, compared to an average daily volume of 109.69M.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
PFE News
Novo Nordisk A/S Chief Executive Officer Mike Doustdar may have lost out to Pfizer Inc. in a $10 billion takeover battle for obesity drug developer Metsera Inc....
Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Meet Your ETF AI Analyst Discover how TipRanks' ETF...
Metsera (MTSR) announced that it has entered into an amended merger agreement with Pfizer (PFE), pursuant to which Pfizer will acquire Metsera for up to $86.25...
Analyst ratings
58%
of 24 ratingsMore PFE News
Healthcare M&A Novo Nordisk gives up battle for Metsera as Pfizer inks $10B deal Nov. 08, 2025 6:42 AM ET Pfizer Inc. (PFE) Stock, NVO Stock, MTSR Stock, NONOF...
Pfizer Inc. (NYSE:PFE) secured a $10 billion deal to acquire obesity drug developer Metsera, Inc. (NASDAQ:MTSR), beating out Novo Nordisk A/S (NYSE:NVO) after a...
New On The Block Miyoko Schinner — the chef and activist who pioneered artisanal vegan cheese — is mounting a bid to buy back Miyoko's, the plant-based dairy b...
Home Investing No Brainer Dividend Stocks To Buy Now Investing No Brainer Dividend Stocks To Buy Now By Vandita Jadeja Nov 6, 2025 11:36 am This post may con...
The Delaware Chancery Court denied Pfizer Inc.’s (NYSE:PFE) request for a temporary restraining order to prevent Metsera, Inc. (NASDAQ:MTSR) from terminating th...
Novo Nordisk (NVO) has again increased its offer for weight-loss drug start-up Metsera (MTSR) in an effort to beat out a sweetened offer from Pfizer (PFE), Drew...
The battle between Pfizer (PFE) and Novo Nordisk (NVO) is "getting ugly," an analyst said Thursday as Metsera (MTSR) stock surged on reports that Pfizer has mat...
